Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 189
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 178
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 689-699
Open Access | Times Cited: 133
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
Marit J. van Gils, A. H. Ayesha Lavell, Karlijn van der Straten, et al.
PLoS Medicine (2022) Vol. 19, Iss. 5, pp. e1003991-e1003991
Open Access | Times Cited: 93
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
Sivan Gazit, Yaki Saciuk, Galit Perez, et al.
BMJ (2022), pp. e071113-e071113
Open Access | Times Cited: 80
Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 40
Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
Lirong Cao, Jingzhi Lou, See Yeung Chan, et al.
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1715-1722
Open Access | Times Cited: 39
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Reem Hoteit, Hadi M. Yassine
Vaccines (2022) Vol. 10, Iss. 6, pp. 919-919
Open Access | Times Cited: 38
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 49
Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
Wiebe Külper‐Schiek, Vanessa Piechotta, Antonia Pilic, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
Nando Reza Pratama, Ifan Ali Wafa, David Setyo Budi, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2180-2180
Open Access | Times Cited: 27
Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate
Aaron Richterman, Amy J. Behrman, Patrick J. Brennan, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e319-e326
Open Access | Times Cited: 22
Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities
Mohammad Shah Alam
Heliyon (2023) Vol. 9, Iss. 2, pp. e13285-e13285
Open Access | Times Cited: 15
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 21
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines
Marit J. van Gils, A. H. Ayesha Lavell, Karlijn van der Straten, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 18
Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections
Suelen H. Qassim, Hiam Chemaitelly, Houssein H. Ayoub, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in Israel
Sivan Gazit, Yaki Saciuk, Galit Perez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron
Ulrike Baum, Eero Poukka, Tuija Leino, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 11
mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia
Rui Li, Hanting Liu, Christopher K. Fairley, et al.
Vaccine (2023) Vol. 41, Iss. 15, pp. 2439-2446
Open Access | Times Cited: 6
Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022
François Blanquart, Clémence Abad, Joëvin Ambroise, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 89-96
Open Access | Times Cited: 6
Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2
Sebastian Alexander Müller, Sydney Paltra, Jakob Rehmann, et al.
iScience (2023) Vol. 26, Iss. 9, pp. 107554-107554
Open Access | Times Cited: 6
Considerations for vaccinating children against COVID-19
John Hart, Darren Suryawijaya Ong, Kulkanya Chokephaibulkit, et al.
BMJ Paediatrics Open (2023) Vol. 7, Iss. 1, pp. e001964-e001964
Open Access | Times Cited: 5
Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, et al.
Journal of Infection and Chemotherapy (2022) Vol. 28, Iss. 9, pp. 1273-1278
Open Access | Times Cited: 9
Third booster vaccination and stopping the Omicron, a new variant of concern
Kiarash Ghazvini, Mohsen Karbalaei, Masoud Keikha
Vacunas (2022) Vol. 23, pp. S103-S110
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top